• Serum Concentrations of E3112 [ Time Frame: Day 1: 0-24 hours; Day 8: 0-24 hours ]
• Change from Baseline in Serum Concentration of E3112 [ Time Frame: Day 1: 0-24 hours; Day 8: 0-24 hours ]
• Peak Concentration (Cmax) of E3112 [ Time Frame: Day 1: 0-24 hours; Day 8: 0-24 hours ]
  Cmax is the maximum observed concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered.
• Time to Peak Concentration (Tmax) of E3112 [ Time Frame: Day 1: 0-24 hours; Day 8: 0-24 hours ]
  Tmax is the time from dosing to reach the maximum observed concentration a drug achieves in a specified compartment or test area of the body after the drug has been administered.
• Area Under the Concentration-time Curve (AUC 0-t) of E3112 [ Time Frame: Day 1: 0-24 hours; Day 8: 0-24 hours ]
  AUC 0-t is area under the concentration-time curve from time 0 to time of last quantifiable concentration for E3112.
• Area Under the Concentration-time Curve (AUC∞) of E3112 [ Time Frame: Day 1: 0-24 hours; Day 8: 0-24 hours ]
  AUC∞ is area under the concentration-time curve from time 0 to infinity of E3112.
• Half-life of Elimination (t1/2) of E3112 [ Time Frame: Day 1: 0-24 hours; Day 8: 0-24 hours ]
  t1/2 is the time required for the concentration of the drug to reach half of its original value.
• Clearance (CL) of E3112 [ Time Frame: Day 1: 0-24 hours; Day 8: 0-24 hours ]
  CL is defined as the rate of drug elimination divided by the plasma concentration of the drug.
• Volume of Distribution (Vd) of E3112 [ Time Frame: Day 1: 0-24 hours; Day 8: 0-24 hours ]
  Vd is the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma.

• Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 to Day 43 ]
• Number of Participants with an Abnormal, Clinically Significant Hematology parameter value [ Time Frame: Day 1 to Day 43 ]
• Number of Participants with an Abnormal, Clinically Significant Clinical Chemistry Parameter Value [ Time Frame: Day 1 to Day 43 ]
• Number of Participants with an Abnormal, Clinically Significant Urine Value [ Time Frame: Day 1 to Day 43 ]
• Number of Participants with Clinically Significant Change in Vital Signs [ Time Frame: Day 1 to Day 43 ]
• Number of Participants with Clinically Significant Change in Electrocardiogram (ECG) [ Time Frame: Day 1 to Day 43 ]
• Number of Participants with Clinically Significant Change in Physical Findings [ Time Frame: Day 1 to Day 43 ]
• Number of Participants with Clinically Significant Change in Ophthalmological Findings [ Time Frame: Day 1 to Day 43 ]
• Percentage of Participants with Serum Anti-E3112 Antibodies [ Time Frame: Day 1 to Day 43 ]

• Drug: E3112
  Intravenous infusion.
• Other: Placebo
  Intravenous infusion.

• Experimental: Cohort 1 Group A: E3112 + Placebo
  E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
  Interventions:

  • Drug: E3112
  • Other: Placebo
• Experimental: Cohort 1 Group B: Placebo + E3112
  Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
  Interventions:

  • Drug: E3112
  • Other: Placebo
• Experimental: Cohort 2 Group A: E3112 + Placebo
  E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
  Interventions:

  • Drug: E3112
  • Other: Placebo
• Experimental: Cohort 2 Group B: Placebo + E3112
  Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
  Interventions:

  • Drug: E3112
  • Other: Placebo
• Experimental: Cohort 3 Group A: E3112 + Placebo
  E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
  Interventions:

  • Drug: E3112
  • Other: Placebo
• Experimental: Cohort 3 Group B: Placebo + E3112
  Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
  Interventions:

  • Drug: E3112
  • Other: Placebo
• Experimental: Cohort 4 Group A: E3112 + Placebo
  E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
  Interventions:

  • Drug: E3112
  • Other: Placebo
• Experimental: Cohort 4 Group B: Placebo + E3112
  Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
  Interventions:

  • Drug: E3112
  • Other: Placebo

Inclusion Criteria:

1. Non-smoking Japanese males aged 20 to 44 years at the time of written, informed consent
2. Body Mass Index (BMI) at screening is 18.5 or more but less than 25.0 kilogram per square metre (kg/m^2)
3. Written, informed consent to participate in the study based on the participant's own free will
4. Willing and able to comply with the requirements in the study after being fully informed of the requirements

Exclusion Criteria:

1. Male participants with reproductive potential who and whose partner do not agree to practice medically appropriate contraception (Note: throughout the study)
2. A history or complication of malignant tumor, lymphoma, leukemia, or lymphoproliferative disorder, a clinically significant disease requiring treatments within 8 weeks before the investigational product treatment, or a history of a clinically significant infection within 4 weeks before the investigational product treatment
3. With a psychiatric, digestive, hepatic, renal, respiratory, endocrine, hematologic, neural, or cardiovascular disease within 4 weeks before the investigational product treatment, a congenital metabolic abnormality, or otherwise a disease that may affect the drug assessments
4. With a surgical history (e.g., resection of the liver, kidney, or digestive tract, etc.) at screening that may affect the pharmacokinetics of the investigational product
5. Suspicion of having a clinically abnormal symptom or an organ impairment that requires treatments based on the history/complications at screening or physical findings, vital signs, electrocardiogram findings, or laboratory values at screening or baseline
6. Testing positive for human immunodeficiency virus (HIV) at screening
7. A positive response to a qualitative test for hepatitis B virus surface antigen (HBs antigen), hepatitis B virus core antigen (HBc) antibody, hepatitis C virus (HCV) antibody, or syphilis
8. Use of a prescription drug within 4 weeks before the investigational product treatment
9. Use of an over-the-counter drug within 2 weeks before the investigational product treatment
10. Receiving a vaccine within 4 weeks before the investigational product treatment
11. Ongoing participation in another clinical study or use of an investigational product or device within 16 weeks before the investigational product treatment while participating in another clinical study
12. Receiving blood transfusion within 12 weeks before the investigational product treatment, providing a whole-blood sample of 400 millilitre (mL) or more between 12 to 4 weeks before the investigational product treatment or a whole-blood sample of 200 mL or more within 4 weeks before the investigational product treatment, or giving blood components by pheresis within 2 weeks before the investigational product treatment